June 25 - The Stevanato Group strengthens its presence in the East with the inauguration, todat, of a new jar and vials production plant in Zhangjiagang, China for "Ompi of China." Stevanato has already invested €27 million in the construction of the plant, which represents an important step in the internationalization and growth strategy of the Padua group. This strategy was launched some years ago, with the opening of new sales offices and new production sites in countries in which it exports the most: North America, South America and the Far East. As for the production site built in 2008 in Monterrey, Mexico, all technologies, equipment, and materials of the new factory in Zhangjiagang were developed by Piombino Dese da Spami, the Groupìs engineering systems division, which manufactures machinery for glass processing.

THE GROUP

The Stevanato Group has 1900 employees, and a turnover of over € 240 million in 2013 (+16% compared to 2012). Its success is mainly due to exports and its manufacturing presence and sales offices in Italy, Slovakia, Denmark, Mexico, the U.S. and China. The Group Stevanato markets its products in 150 countries around the world, operating through two divisions: Pharmaceutical Systems and Engineering Systems. The Group produces insulin vials and glass containers for pharmaceutical use under the brand Ompi. The plant in Zhangjiagang, in the Jiangsu Province, covers an area of 30,000 sqm (8,500 sqm of factory, of which 4,000 for production lines and 1,300 for final aseptic packaging). At full capacity, which will be reached at the end of phase 1 (2016), the plant will have as many as 16 production lines equipped with the latest technology in vial and bottle production. It will employ a total of 250 qualified workers, trained in other plants of the Group. Currently, the plant employs 115 workers.